CARB-X awards LimmaTech US$6.5 million to advance clinical development of LBT-SA7 “We are grateful for the significant support from CARB-X, which is not only instrumental in accelerating the ...
aureus). In this context, the company also announced the award of US$6.5 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance the clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback